Achilles Therapeutics PLC
698
Company Profile
Business description
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Contact
245 Hammersmith Road
LondonW6 8PW
GBRT: +44 2081544600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
215
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,158.70 | 9.80 | 0.12% |
| CAC 40 | 8,035.24 | 58.96 | -0.73% |
| DAX 40 | 22,827.56 | 171.59 | -0.75% |
| Dow JONES (US) | 41,710.11 | 243.21 | -0.58% |
| FTSE 100 | 8,644.75 | 57.24 | -0.66% |
| HKSE | 23,689.72 | 530.23 | -2.19% |
| NASDAQ | 17,581.01 | 110.61 | -0.63% |
| Nikkei 225 | 37,677.06 | 74.82 | -0.20% |
| NZX 50 Index | 12,113.54 | 58.82 | 0.49% |
| S&P 500 | 5,623.46 | 39.43 | -0.70% |
| S&P/ASX 200 | 7,931.20 | 12.30 | 0.16% |
| SSE Composite Index | 3,364.83 | 44.12 | -1.29% |